Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma

October 27, 2022

Patients with multiple myeloma who have already undergone 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, may now receive treatment with teclistamab-cqyv (Tecvayli).

Frontline Ibrutinib Plus Venetoclax Reduces Relapse in Elderly Patients with Chronic Lymphocytic Leukemia

October 15, 2022

A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.